logo.png
Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization
November 24, 2021 17:15 ET | Allarity Therapeutics A/S
Press release Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity A/S" or the "Company") hereby announces a voluntary offer and offer document to the shareholders of...
logo.png
Grant of New Warrants and Resolutions on Existing Warrants
November 24, 2021 15:50 ET | Allarity Therapeutics A/S
Company Announcement Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity" or the "Company") today announced that the Board of Directors of Allarity has exercised the...
logo.png
Allarity Therapeutics Publishes Interim Report for the Period January – September 2021
November 23, 2021 02:00 ET | Allarity Therapeutics A/S
Press Release Hørsholm, Denmark (November 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – September...
logo.png
Minutes of Extraordinary General Meeting held on 22 November 2021
November 22, 2021 18:00 ET | Allarity Therapeutics A/S
Company Announcement Minutes of Extraordinary General Meeting held on 22 November 2021The English part of this parallel document in Danish (attached) and English is an unofficial translation of the...
logo.png
Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus
November 11, 2021 02:30 ET | Allarity Therapeutics A/S
Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (“British” variant),beta variant B.1351 (“South African” variant),...
logo.png
NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALLARITY THERAPEUTICS A/S TO BE HELD ON NOVEMBER 22, 2021
November 05, 2021 17:11 ET | Allarity Therapeutics A/S
Press release THE BOARD OF DIRECTORS HEREBY CONVENES an extraordinary general meeting of the shareholders of Allarity Therapeutics A/S (“Allarity A/S”) to be held on November 22, 2021 at 10:00 am...
logo.png
U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq
November 05, 2021 16:48 ET | Allarity Therapeutics A/S
  An application for listing on the U.S. Nasdaq Stock Market for the shares of Allarity Therapeutics, Inc. (Delaware) (Nasdaq: ALLR) has been made conditioned upon shareholder approval of the...
logo.png
Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate
September 23, 2021 03:00 ET | Allarity Therapeutics A/S
  Integrated solution for process development and manufacturing of drug substance and drug product will facilitate the advancement of clinical developmentThe agreement meets Allarity’s needs for...
logo.png
Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress
September 16, 2021 04:00 ET | Allarity Therapeutics A/S
Patient selection using DRP® score of 50% resulted in a median survival of 15.0 monthPatient selection using DRP® score of 67% resulted in a median survival of 20.6 months Press Release Hørsholm,...
logo.png
Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3
September 15, 2021 17:55 ET | Allarity Therapeutics A/S
Subscription is approximately 9.5 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Press...